Smith & Nephew's Supartz Is Third Player In HA Osteoarthritis Market

Smith & Nephew's 400-rep sales force plans to emphasize the extensive clinical experience behind the firm's Supartz hyaluronic acid-based injectable treatment for osteoarthritis of the knee in marketing the product to orthopedic surgeons.

More from Archive

More from Medtech Insight